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Abstract
Aim of the Study: The regulation and actions of fibroblast growth factor 21 (FGF21) are 
responsive to energy status and macronutrient balance, and investigations of FGF21 in normal 
pregnancy, which could be informative for FGF21 biology, are seldom. The goal of our study was 
to examine FGF21 levels in a contemporaryhealthy, pregnant population.
Methods: We phenotyped 43 women with overweight and obesity during pregnancy for weight, 
body composition, and fasting blood. Serum FGF21 was measuredduring the first and third 
trimesters. Placentas were collected at delivery.
Results: Maternal FGF21 concentrations were positively correlated with body mass index and 
adiposity, but not lean mass or glucose homeostasis. In support of our hypothesis, FGF21 
concentrations significantly increased from the first to third trimester of pregnancy (0.105 vs. 
0.256 ng/mL, p<0.0001). Changes in FGF21concentrations across pregnancy were not associated 
with changes in body weight or composition but inversely with the change in fasting glucose. 
FGF21 mRNA levels in placenta were very low and do not likely contribute to FGF21 in the 
maternal circulation.
Conclusions: FGF21 increases throughout pregnancyin our healthy cohort with overweight and 
obesity, independent of the placenta, and does not appear to be sensing the changes in energy 
balance (reflected in the change in maternal energy stores), but changes in macronutrient status. 
Thus, we propose FGF21 may be a potential signal of maternal nutrient status in pregnancy.
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Fibroblast growth factor 21 (FGF21) is secreted in response to energy imbalance for the 
regulation of energy and nutrient metabolism. First discovered as a glucose sensitizer of 
adipose tissue, FGF21 has since been shown in both animal models and human studies to 
regulate glucose and lipid metabolism under various states of energy balance1. Metabolically 
challenged transgenic models overexpressing FGF21 and pharmacological administration of 
FGF21 to obese and diabetic animals and humans have revealed FGF21 to be capable of 
reducing body weight, protecting against diet induced obesity, improving glucose tolerance, 
and improving lipid profiles1–7. However, cross sectional studies of the human population 
show that FGF21 is elevated in clinical conditions of energy or nutrient excess, such as 
obesity and type 2 diabetes8–15. FGF21 is also positively correlated with metabolically 
unfavorable characteristics, such as hyperinsulinemia, insulin resistance, 
hypertriglyceridemia, and total cholesterol11,14,16–22.
Pregnancy is a state of energy flux with energy and macronutrient demand increasing at 
variable rates and in response to various cues throughout gestation. Considering the impact 
of energy and macronutrient balance on FGF21 expression and action, understanding how 
FGF21 is regulated and/or acting in pregnancy, particularly in the presence of excess 
adiposity, could be highly informative to FGF21 biology. Conversely, given that adequate 
maternal nutrition (both over- and under-nutrition) is important for optimal pregnancy 
outcomes, FGF21 may serve as a novel hormone to indicate patients at risk. Descriptions of 
FGF21 in the pregnant population are surprisingly limited to cross sectional studies in 
women with gestational diabetes or preeclampsia, with the majority of these studies showing 
FGF21 elevated in these conditions22–26. These reports also confirm well established 
associations between FGF21 and an unfavorable metabolic milieu described in the non-
pregnant state. For example, FGF21 in late pregnancy positively correlates with triglycerides 
and insulin resistance and inversely with adiponectin and HDL-cholesterol22,23,25. The 
current knowledge of FGF21 biology in pregnancy is in need of more in depth studies 
throughout pregnancy. The aim of this study was to examine FGF21 levels in pregnant 
womenin a contemporary cohort with overweight and obesity and to understand the role 
maternal energy stores and the placenta mayplay on maternal FGF21 secretion. We 
hypothesized FGF21 concentrations would be higher in women with increased adiposity. 
Moreover, commensurate with the increase in energy status (fat mass) and glucose 
intolerance (macronutrient balance) across pregnancy, we hypothesized that maternal FGF21 
would increase throughout gestation.
MATERIALS AND METHODS
Study population
One hundred and fourteen pregnant women enrolled in the Expecting Success (n=54, 
NCT01610752) or the MomEE (n=60, NCT01954342) studies at Pennington Biomedical 
Research Center (PBRC) in Baton Rouge, Louisiana were potentially eligible for inclusion 
in this ancillary study. As detailed elsewhere, participants were recruited primarily from 
obstetrical offices, augmented by print and social media advertisements27. For entry into the 
parent studies, participants were required to be healthy, overweight or obese women 
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(BMI>25kg/m2), aged 18–40 years with a single, viable, first trimester pregnancy (<14 
weeks gestation). Patients were excluded from the parent studies for pregnancy-related 
conditions (known fetal anomaly, planned termination of pregnancy or adoption of infant, 
history of ≥3 consecutive miscarriages), pre-existing hypertension or diabetes (diagnosis 
prior to pregnancy, elevated HbA1c, or first trimester OGTT diagnosis of diabetes), 
psychological criteria (history or current psychotic disorder, current major depressive 
episode, bipolar disorder, history of anorexia or bulimia, current eating disorder, actively 
suicidal), medications (metformin, systemic steroids, antipsychotic agents, anti-seizure 
medications, or medications for ADHD), HIV, severe anemia, contraindications to 
exercise28, prior or planned (within one year of expected delivery) bariatric surgery, or 
recent history of or current smoking, alcohol, or drug use.
Of the 114 participants in the parent studies, 43 satisfied inclusion criteria for this ancillary 
study, provided consent for future use of biospecimens (i.e. blood and/or placenta), and had 
the required clinical data available at one or more time points for analysis. Briefly, the 
Expecting Success Study (NCT01610752) was an interventional study testing the efficacy of 
a lifestyle intervention designed to help overweight and obese pregnant women gain the 
recommended amount of weight in pregnancy. The MomEE Study (NCT01954342) was an 
observational study determining energy requirements of overweight and obese women 
across pregnancy. Both parent studies and this ancillary study were approved and monitored 
by the PBRC Institutional Review Board and all participants provided verbal and written 
consent prior to study initiation.
Clinic Assessments
For both the Expecting Success and MomEE Studies, study visits were performed in the first 
trimester (<16 weeks) and third trimester (35–36 weeks) in the morning following an 
overnight fast. Body weight, body composition, and blood measurements were collected in 
accordance with standard operating procedures of Pennington Biomedical Research Center 
to ensure scientific rigor and reproducibility.
Maternal Anthropometrics
Body weight was recorded twice with the participant fasting and wearing a hospital gown 
and undergarments only. The two recorded weights were averaged and the hospital gown 
weight subtracted. Body mass index was calculated as body weight (kg) divided by the 
square of study-measured height (m2). Body composition was assessed by air displacement 
plethysmography using a BOD POD® (COSMED, Chicago, IL) and fat mass and fat free 
mass were calculated from body volume as determined by the BOD POD® using equations 
developed by van Raaij et al. as previously validated29,30.
Blood chemistry
Serum glucose and insulin were assayed with the Beckman Coulter DXC 600 Pro (Beckman 
Coulter Inc., Brea, CA). FGF21 was measured in duplicate by sandwich enzyme-linked 
immunosorbent assay (ELISA) according to manufacturer instructions (RD191108200R, 
Fibroblast Growth Factor Human ELISA, Biovendor, Brno, Czech Republic). Serum was 
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diluted 1:2 (125μL of serum in 125μL of dilution buffer) before analysis. The detectable 
concentration by the assay is 0.03 ng/mL. The intra-assay coefficient of variation was 3.9%.
Placenta collection and quantitative real time PCR
Placenta samples were collected, dissected and frozen within two hours of delivery. Samples 
were dissected at four separate sites of the placental disc and stored by section (basal plate, 
villous tissue, and chorionic plate) at −80°C until being thawed for study. Experiments in 
this study used villous tissue snap frozen within two hours of delivery and pooled from all 
four collection sites. PlacentalRNA was isolated from flash-frozen tissue with the RNeasy 
Mini Kit (QIAGEN). Samples were quantified by Nanodrop and all samples had 260:280 
and 260:230 ratios greater than 1.75. A 2000ngsample of RNA was reverse transcribed with 
the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) into cDNA. 
Quantitative real-time PCR was performed with 20ng of cDNA, 300nM of each forward and 
reverse primer, and iTaq universal SYBR green mastermix. The PCR protocol was 
performed on a 7900HT PCR Machine (ThermoFisher Scientific, Waltham, MA) beginning 
with one cycle at 95⁰C for 10 minutes, then 40 cycles of 95⁰C for 15 seconds and 59⁰C for 1 
minute, and ended with a dissociation curve analysis. Primer sequences unique for each 
target gene were designed with primer BLAST to span exon-exon junctions (Table 1). The 
geometric mean of SDHA and TBP was used as an endogenous control and data was 
analyzed by ΔΔCt method.
Statistical analysis
Data are presented as mean ± standard error. Fasting insulin and HOMA-IR were 
logarithmically transformed. Statistical significance was determined by Spearman’s 
correlation or paired student’s t-tests when appropriate. Tests were performed with 
significance level α=0.05, and findings considered significant when P<α.
RESULTS
Participants
The study cohort was 29±5 years old at the time of enrollment and was comprised of 
participants who self-identified as Caucasian (n=37), black (n=5) and other (n=1) (Table 2). 
Using first measured study height and weight (<14 weeks gestation), 14 participants were 
overweight (BMI 25–29.9kg/m2) and 29 participants were obese (BMI ≥ 30 kg/m2) with 16 
classified as obeseclass I, 7 obeseclass II, and 6 obeseclass III. All participants were in good 
health at enrollment. During study participation, four participants were diagnosed with 
gestational diabetes mellitus (GDM) (three treated with glyburide and one with glipizide), 
two with preeclampsia (one receiving magnesium sulfate during labor), and one participant 
with both GDM and PE (treated with diet only and magnesium sulfate during labor 
respectively)(described in Supplement Table 1).
Pattern of FGF21 in human pregnancy
In fasting serum samples collected from healthy women in the first and third trimester of 
pregnancy, FGF21 concentrations were found to be highly variable. In the first trimester 
(n=29), FGF21 concentrations ranged from 0.035 to 0.256 ng/mL (Figure 1A) and an even 
Sutton et al. Page 4













larger degree of variability was observed in the third trimester (n=43, range 0.056–0.850 
ng/mL, Figure 1B). First trimester FGF21 concentrations showed ten-fold less variance 
compared to third trimester concentrations, 0.003 versus 0.033 respectively (p<0.0001). For 
participants with FGF21 concentrations measured at both the first and third trimesters 
(n=29), FGF21 concentrations increased across pregnancy and were more than 2-fold higher 
in the third trimester of pregnancy (35–36 weeks) compared to concentrations measured in 
the first trimester (<16 weeks), 0.256 vs. 0.105 ng/mL respectively (Figures 1C and 1D).
FGF21 is correlated with maternal body size and adiposity throughout pregnancy
In non-pregnant individuals, FGF21 is elevated with higher BMI andincreased adiposity14. 
In the pregnant state, we found FGF21 concentrations are significantly and positively 
correlated with maternal BMI in both the first (ρ=0.48, p=0.008) and third trimesters 
(ρ=0.40, p=0.008) (Figures 2A and B). However, FGF21 correlated to body weight in the 
first trimester only (ρ=0.39, p=0.04, data not shown).FGF21 concentrations are also strongly 
and significantly correlated with maternal adiposity reported as total fat mass (kg) in both 
the first and third trimesters (1st trimester: ρ=0.47, p=0.01; 3rd trimester: ρ=0.39, p=0.01) 
(Figures 2Cand 2D). FGF21 concentration was not significantly correlated with maternal fat 
free mass in either trimester (1st trimester: ρ= 0.21, p=0.26, 3rd trimester: ρ= −0.06, p=0.68) 
(data not shown).
FGF21 is not correlated with glucose homeostasis in normoglycemic pregnancy
FGF21 has been shown to positively correlate with fasting glucose, fasting insulin, and 
insulin resistance in animal models and cross sectional, non-pregnant human 
studies8,11,16–18. In our population of pregnant women with majority normal glucose 
tolerance and maternal overweight or obesity, no significant relationships between FGF21 
and fasting glucose (p=0.61 and 0.63 respectively, data not shown), fasting insulin (p=0.23 
and 0.54respectively, data not shown), or HOMA-IR (p=0.24 and 0.52 respectively, data not 
shown) were observed in either the first or third trimester.
Change in glucose, not adiposity, correlates with change in FGF21 across pregnancy
In an effort to understand if alterations in maternal characteristics throughout gestation may 
explain the increase in FGF21, we tested for relationships between the change in FGF21 
(absolute and percent) and changein known contributors of FGF21 in the non-pregnant state, 
namely adiposity and metabolic status. As expected, body weight, fat mass, fat free mass, 
and fasting insulin each increased from the first to the third trimester, although fasting 
glucosemarginally decreased (Table 2). Although we observed significant relationships with 
body composition, namely adiposity, at single time points, the changes in these parameters 
across pregnancy were not associated with the changes in FGF21 concentrations measured 
across the same time interval (Table 3). However, the change in FGF21 concentrations was 
significantly and inversely correlated with the change in fasting glucose (ρ= −0.44, p=0.02). 
No relationship was observed between changes in FGF21 and alterations in insulin or 
HOMA-IR (ρ= −0.16, p=0.40 and ρ= −0.26, p=0.18 respectively).
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The placenta is not a primary source of FGF21 production in pregnancy
Considering the increase in FGF21 is not correlated with changes in maternal energy 
storesand considering previous studies24,31,32 that suggest FGF21 may be secreted by the 
placenta, we hypothesized that the increase in FGF21 concentrations across pregnancy may 
originate from products of conception (i.e. placenta and fetus). Utilizing two different sets of 
primers including the primers reported in past studies31, we were unable to detect 
meaningful and replicable quantities of FGF21 transcript in human placenta by qPCR. These 
observations are not due to poor sample quality or error in qPCR protocol. The RNA 
extraction protocol used results in a RIN of 7 in human placenta; moreover, we were able to 
measure over 20 additional genes (including housekeeping genes SDHA and TBP) with 
resulting CTs as would be expected based on published findings in human placenta.
DISCUSSION
In this study, we report FGF21 levels in a pregnant population with pregravid overweight or 
obesity. The three novel observations from this body of work are that circulating FGF21 
measured in fasting conditions is correlated with maternal body mass indexand adiposity at 
cross sectional timepoints throughout pregnancy, FGF21 concentrations increase across 
pregnancy, and this increase in FGF21 does not appear to be coming from the placenta or a 
change in maternal energy stores but with alterations in maternal glucose concentrations.
The relationship of FGF21, BMI, and adiposity has been well reported in non-pregnant 
animal models and human populations10,14,15,18. In this study, we demonstrate FGF21 
concentrations positively correlate with maternal body mass index and adiposity in pregnant 
women in both the first and third trimesters. Considering pregnancy is a time for increased 
energy deposition in preparation for postpartum energy demands, e.g. lactation, these 
findings show the relationship between FGF21 and adiposity observed in non-pregnant 
states holds in cross sectional analysis performed at different timepoints across pregnancy. 
However, it is important to note the individual changes in adiposity across pregnancy did not 
predict the variations in FGF21 concentrations. These data suggest that the physiological 
driversfor deposition of maternal energy in fat mass are independent of changes in FGF21.
Notably, we were unable to confirm that high concentrations of FGF21 are present in 
pregnant individuals with increasing levels of glucose intolerance. Lack of support for this 
relationship in our population could be due to insufficient statistical power because we 
excluded participants with pregravid diabetes and impaired glucose tolerance in their first 
trimester (HbA1c > 6.5% and/or failed 75g oral glucose tolerance test). Although five 
participants were diagnosed with GDM during study participation, this initial exclusion 
likely limited the variability in glucose dysfunction within our cohort (fasting glucose 
ranged 72–109 mg/dL) despite the large range of maternal BMI(25.6 to 45.4 kg/m2). While 
fasting insulin and HOMA-IR showed moderate distribution among participants across 
pregnancy (see Table 2), glucose regulation appeared well controlled. Indeed, the percent 
change in fasting glucose (from the first to third trimester) ranged from −20% to +9%, with 
fasting glucose decreasing in two-thirds of participants. Therefore, there was limited 
variability in measures of glucose homeostasis for comparison to FGF21. Future studies 
need to be conducted in pregnant women with varying degrees of glucose tolerance to 
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further elucidate the role of FGF21 in response to the worsened maternal glucose 
homeostasis throughout pregnancy.
We observed FGF21 concentrations were less variable and significantly lower in the first 
trimester compared to the third trimester of pregnancy. Considering FGF21 has been 
reported to be produced by the human placenta by two separate laboratories (in one study by 
ELISA of placenta explant media 24 and two other studies by qPCR of flash frozen human 
placenta samples31,32), it was reasonable to hypothesize that the increase in circulating 
FGF21 could be attributed to placenta tissue. Although, after extensive qPCR experiments in 
term human placenta from a subset of our cohort (n=19), we were unable to quantify 
expression of FGF21 in the samples studieddespite detection of other genes such as SDHA 
and TBP. We are therefore confident the human placenta is not contributing meaningful 
amounts of FGF21 into the maternal circulation.Instead, considering evidence of robust 
elevation in hepatic FGF21 mRNA throughout pregnancy recently reported in wild-type 
mice33, we posit the elevation in circulating FGF21 observed in our human cohort is 
likelyresultant from the liver. Moreover, there is extensive evidence showing FGF21 
synthesis and secretion by adipocytes in rodents and humans, and it may also be likelythat 
maternal adipocytesare contributing in part to this FGF21 elevation considering the increase 
in fat mass across pregnancy14,34.
FGF21 has been regularly shown to correlate with glucose homeostasis in non-pregnant and 
pregnant populations with glucose dysfunction which could be another possible explanation 
for the change in FGF21 across pregnancy. Despite the limited variability of glucose 
homeostasis within our cohort, we observed a significant negative correlation between 
alterations in FGF21 and changes in fasting glucose. Of note, there was not a significant 
correlation between change in insulin or HOMA-IR and change in FGF21. The original role 
elucidated for FGF21 was as a glucose regulator, however the relationship between FGF21 
and glucose regulation in pregnancy merits further investigation as we made these 
observations within a healthy population with little variability.
Longitudinal measurements of FGF21, body composition assessments in pregnancy by BOD 
POD®, as well as the availability of archived placenta tissue provide strength to our study. 
However, our study does have limitations. First is our small sample size. In an effort to 
maximize resources, we leveraged existing data and archived biospecimens from two parent 
studies (totaling n=114 at the time of analysis) to test our hypothesis. Considering the 
necessary data and biospecimens to answer our question (i.e. archived third trimester serum, 
data collected in the first and third trimesters, and consent for future use of biospecimens 
and data), only 43 of the 114 enrolled participants were eligible for this 
ancillary.Furthermore, our sample is primarily made up of Caucasian women and 
exclusively of women with overweight and obesity. Indeed, replication of these results in a 
larger and more diverse cohort as well as a normal weight cohortwould be advantageous 
next steps. Second, 21 of 43 subjects participated in a lifestyle intervention aimed 
toattenuate gestational weight gain during pregnancy.We conductedadditional analysesto 
investigate the potential influence of the intervention and found no differences across 
pregnancy for individuals receiving or not receiving the intervention, including change in 
FGF21,weight, BMI, fat mass, fat free mass, glucose, insulin, or HOMA-IR (Supplement 
Sutton et al. Page 7













Table 3). There were significant differences in BMI, weight, and fat mass at enrollment 
between individuals receiving the intervention compared to no intervention (Supplement 
Table 2). However, this finding is expected as our “no intervention” group is a compilation 
of a subset of the control group from the Expecting Success Study (n=6) whose inclusion 
criteria was BMI ≥ 25kg/m2 and participants from the MomEE Study (n=16) which did not 
have an intervention and whose inclusion criteria BMI ≥ 30kg/m2.
Since the changes in FGF21 were associated with changes in fasting glucose and not with 
the changes in body energy stores (i.e. weight or fat mass), we hypothesize that variations in 
acute energy status, such as with the maternal diet that influence both tissue deposition and 
glucose regulation, might be involved. In summary, we observed maternal FGF21 is 
positively correlated with maternal body mass index and adiposity before and throughout 
pregnancy, and FGF21 is likely responsive to short-term changes in macronutrient balance 
induced by maternal diet rather than long-term changes in energy balance reflected in the 
maternal energy stores.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Serum FGF21 concentrations in the first and third trimesters of our study population.
(A) Distribution of FGF21 in the 1st trimester (<16 weeks), (B) distribution of FGF21 in the 
3rd trimester (35–36 weeks), (C) individual and mean ± SEM serum FGF21 measured 
across pregnancy, (D) individual change in serum FGF21 between first and third trimesters, 
*p<0.0001.
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Figure 2: Serum FGF21 is significantly correlated with maternal body mass index and fat mass 
throughout pregnancy.
(A) 1st trimester BMI, (B) 3rd trimester BMI, (C) 1st trimester fat mass, (D) 3rd trimester fat 
mass.
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Table 2:
Participant Characteristics
Pre-pregnancy 1st Trimester 3rd Trimester p value*
Age at enrollment 29.1 (5.0)
Parity (0/1/2/3/4) 20/20/0/2/1
Race
    Black 5 (12%)
    White 37 (86%)
    Other 1 (2%)
BMI Class
    Overweight 13 14 2
    Obese- Class I 17 16 17
    Obese- Class II 8 7 14
    Obese- Class III 5 6 10
BMI (kg/m2) 32.8 (5.4) 33.5 (5.3) 36.6 (4.7) <0.0001
Weight (kg) 86.8 (14.5) 88.6 (14.5) 96.9 (13.3) <0.0001
Fat mass (kg) 40.4 (10.5) 41.8 (9.7) 0.04
Lean mass (kg) 48.3 (6.1) 55.3 (6.1) <0.0001
Fasting glucose (mg/dL) 84.6 (8.0) 81.5 (7.6) 0.002
Fasting insulin (mU/L) 12.4 (7.9) 16.8 (9.3) <0.0001
HOMA-IR 2.7 (2.0) 3.4 (2.1) 0.002
Values reported as mean ± standard deviation
*
represents significant differences between first and third trimester
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Table 3:
Spearman correlations between percent change in FGF21 and percent change in body size, composition and 
macronutrient balance from the first to third trimesters
ρ P value
Change in body weight 0.17 0.38
Change in BMI 0.17 0.38
Change in fat mass 0.16 0.41
Change in fat free mass 0.14 0.48
Change in glucose -0.44 0.02
Change in insulin -0.16 0.40
Change in HOMA-IR -0.26 0.18
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